The Zilver® PTX® single arm study: 12-Month results from the TASC C/D lesion subgroup

Journal of Cardiovascular Surgery

Volumn 54, Issue 1, 2013, Pages 115-122

  Bosiers, M ^a   Peeters, P ^b   Tessarek, J ^c   Deloose, K ^a   Strickler, S ^d  

^a AZ St Blasius ^*  (Belgium)

^b IMELDA HOSPITAL   (Belgium)

^c ST BONIFATIUS HOSPITAL   (Germany)

^d Med Institute Inc Lafayette   (United States)

Author keywords

Drug eluting stents; Femoral artery; Paclitaxel; Peripheral arterial disease

Indexed keywords

PACLITAXEL; PTX; UNCLASSIFIED DRUG; ZILVER;

AGED; ARTICLE; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY; NITINOL STENT; PROSPECTIVE STUDY; STENT FRACTURE; WALKING SPEED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FEMORAL ARTERY; FOLLOW UP; METHODOLOGY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PROSTHESIS; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

MLCS; MLOWN;

EID: 84874426013     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003;37:149-55. (Pubitemid 36236959)
2. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg 2006;44:510-7.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75.
4. Erasmi H, Walter M, Schmitz-Rixen T, Kristen F. [Preliminary results of a prospective randomized study vascular replacement above the knee]. Zentralbl Chir 1996;121-228-33.
5. Abbott WM, Green RM, Matsumoto T, Wheeler JR, Miller N, Veith FJ et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. J Vasc Surg 1997;25:19-28. (Pubitemid 27081605)
6. Green RM, Abbott WM, Matsumoto T, Wheeler JR, Miller N, Veith FJ et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. 2000;31:417-25. (Pubitemid 30158002)
7. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004;40:924-31. (Pubitemid 39535222)
8. Jensen LP, Lepantalo M, Fossdal JE, Roder OC, Jensen BS, Madsen MS et al. Dacron or PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. Eur J Vasc Endovasc Surg. 2007;34:44-9. (Pubitemid 46863199)
9. Nguyen LL, Lipsitz SR, Bandyk DF, Clowes AW, Moneta GL, Belkin M et al. Resource utilization in the treatment of critical limb ischemia: The effect of tissue loss, comorbidities, and graft-related events. J Vasc Surg. 2006;44:971-5; discussion 975-976.
10. Nicoloff AD, Taylor LM, Jr., McLafferty RB, Moneta GL, Porter JM. Patient recovery after infrainguinal bypass grafting for limb salvage. J Vasc Surg 1998;27:256-63; discussion 264-256.
11. Wengrovitz M, Atnip RG, Gifford RR, Neumyer MM, Heitjan DF, Thiele BL. Wound complications of autogenous subcutaneous infrainguinal arterial bypass surgery: predisposing factors and management. J Vasc Surg 1990;11:156-61; discussion 161-153.
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-312.
13. Nowygrod R, Egorova N, Greco G, Anderson P, Gelijns A, Moskowitz A et al. Trends, complications, and mortality in peripheral vascular surgery. J Vasc Surg 2006;43:205-16. (Pubitemid 43221907)
14. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59:16-23.
15. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112:2833-9. (Pubitemid 41641678)
16. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92:641-9.
17. Hill R BA, Bakhai A, Dickson R, Dundar Y, Haycox A et al. Liverpool Reviews and Implementation Group. Health Technol Assess Rep 2004;8:142-242.
18. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
19. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18:613-23.
20. B K. The Resilient Trial: 12-Month Analysis. Paper presented at: Transcatheter Cardiovascular Therapeutics; Oct 23, 2007; Washington, DC.
21. SR R. ABSOLUTE results. Paper presented at: Multidisciplinary European Endovascular Therapy (MEET); June 26-29, 2008; Cannes, French Riviera.
22. Markose G, Miller FN, Bolia A. Subintimal angioplasty for femoro-popliteal occlusive disease. J Vasc Surg 2010;52:1410-6.
23. Nydahl S, Hartshorne T, Bell PR, Bolia A, London NJ. Subintimal angioplasty of infrapopliteal occlusions in critically ischaemic limbs. Eur J Vasc Endovasc Surg 1997;14:212-6. (Pubitemid 27448108)
24. Vraux H, Hammer F, Verhelst R, Goffette P, Vandeleene B. Subintimal angioplasty of tibial vessel occlusions in the treatment of critical limb ischaemia: mid-term results. Eur J Vasc Endovasc Surg. 2000;20:441-6. (Pubitemid 32051129)
25. Laxdal E, Jenssen GL, Pedersen G, Aune S. Subintimal angioplasty as a treatment of femoropopliteal artery occlusions. Eur J Vasc Endovasc Surg. 2003;25:578-82. (Pubitemid 36701799)
26. Desgranges P, Boufi M, Lapeyre M, Tarquini G, van Laere O, Losy F et al. Subintimal angioplasty: feasible and durable. Eur J Vasc Endovasc Surg. 2004;28:138-41. (Pubitemid 38967266)
27. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-88. (Pubitemid 43872689)
28. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-9. (Pubitemid 46842791)
29. Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009;32:720-6.
30. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J et al. Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-50.
31. G A. Interim results of the VIBRANT trial. Paper presented at: Vascular Interventional Advances; Oct 20-23, 2009; Las Vegas NV.
32. Tessarek J. Drug eluting technologies for PAOD. Italian J Vasc Endovasc Surg. 2011;18:225-33.
33. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-9.
34. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10. (Pubitemid 44907633)
35. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-8. (Pubitemid 40354849)
36. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394-401.
37. Diehm N, Baumgartner I, Jaff M, Do DD, Minar E, Schmidli J et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J. 2007;28:798-805. (Pubitemid 47343592)